Hamburg, Germany | Oxford, UK | Barcelona, Spain - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) and Almirall Prodesfarma S.A., the leading Spanish multinational company, today announced that they have entered into a two-year library synthesis agreement.
 
Applying leading skills in high-speed parallel synthesis, medicinal and computational chemistry Evotec will design and synthesise for Almirall several thousand drug-like compounds across a wide range of chemical templates. With Evotec's state-of-the-art integrated autopurification and analytical platforms each compound will be of the highest purity to deliver high quality results in Almirall's pharmaceutical screening and medicinal chemistry programmes.
 
Dr Mark Ashton, Executive Vice President Business Development Services at Evotec, said: "We are delighted that Almirall has chosen Evotec as a long-term partner for this substantial library project. We are confident that our proprietary templates and innovative approaches in creating novel molecules will quickly deliver drug-like compounds to support our partner in their discovery of new drugs."
 
"In the process of selecting the right partner for our ambitious library project, we were impressed by Evotec's reputation and the company's impressive track record in designing and delivering diverse and focused compound libraries," said Dr José Mª Palacios, General Director for Research & Development at Almirall. "Their wide experience, together with their excellent communication, project management skills and understanding of the logistics of delivering on this type of library project has supported our decision to choose Evotec as our long-term partner."
 
Evotec has years of experience in library synthesis and is a proven, world-leader in the design and delivery of high quality compound libraries. With over 1,000 man years of experience in parallel synthesis technology and the critical mass to meet its customers' needs in an effective and efficient manner, Evotec has delivered in excess of 1,000,000 discrete compounds to date.

Contact: Anne Hennecke, Director, Investor Relations & Corporate Communications, Evotec AG, Phone: +49-40-56081-286, anne.hennecke@evotec.com
Contact: Anne Hennecke, Director, Investor Relations & Corporate Communications, Evotec AG, Phone: +49-40-56081-286, anne.hennecke@evotec.com